viral
exacerb
continu
repres
major
burden
term
morbid
mortal
health
care
cost
associ
asthma
greatest
risk
acut
asthma
sever
airway
diseas
poor
asthma
control
group
establish
asthma
acut
exacerb
trigger
viru
infect
remain
seriou
caus
increas
morbid
rang
novel
therapi
emerg
treat
asthma
particular
target
group
poor
diseas
control
case
efficaci
judg
abil
reduc
frequenc
acut
exacerb
critic
develop
new
treatment
approach
improv
understand
virushost
interact
context
asthmat
airway
requir
research
virolog
diseas
physiolog
model
conjunct
detail
phenotyp
characteris
asthma
patient
identifi
target
amen
therapeut
intervent
articl
histori
global
initi
asthma
gina
defin
asthma
heterogen
diseas
usual
character
chronic
airway
inflamm
defin
histori
sporad
respiratori
symptom
vari
sever
accompani
variabl
expiratori
airflow
limit
exacerb
repres
deterior
symptom
lung
function
stabl
statu
requir
increas
medic
unschedul
hospit
visit
impact
asthma
exacerb
substanti
account
total
expenditur
asthma
care
remain
substanti
ongo
challeng
clinic
manag
diseas
develop
nation
australia
asthma
remain
frequent
caus
acut
admiss
hospit
shortact
receptor
agonist
saba
revers
acut
bronchoconstrict
remain
mainstay
asthma
therapi
use
treat
acut
exacerb
activ
airway
smooth
muscl
caus
relax
bronchodil
control
sever
diseas
inhal
corticosteroid
ic
remark
effect
antiinflammatori
drug
remain
frontlin
prevent
therapi
asthma
sinc
earli
ic
prevent
worsen
symptom
control
inflamm
via
sever
mechan
includ
glucocorticoid
receptor
gr
interact
neg
glucocorticoid
respons
element
gre
site
transrepress
also
occur
via
grsteroid
bind
proinflammatori
transcript
factor
histon
modif
anoth
mechan
inflammatori
gene
express
suppress
glucocorticoid
also
exhibit
system
side
effect
often
mediat
grsteroid
complex
bind
gre
site
lead
gene
transactiv
effect
icsbas
prevent
medic
asthma
univers
patient
moder
sever
persist
asthma
altern
approach
treatment
necessari
rather
increas
dose
ic
patient
prescrib
combin
therapi
consist
ic
longact
receptor
agonist
laba
administ
via
singl
inhal
prepar
contain
ic
laba
combin
therapi
offer
advantag
icsonli
inhal
treatment
use
reliev
prevent
lead
better
symptom
control
reduc
risk
exacerb
lower
dose
ic
mechan
action
combin
therapi
investig
laba
shown
augment
antiinflammatori
antiprolif
effect
ic
synergist
suppress
express
potenti
immuopathogen
chemokin
rhinoviru
rv
infect
bronchial
epitheli
cell
bec
virusinduc
asthma
occur
despit
optim
use
corticosteroid
led
develop
addit
therapi
target
inflammatori
pathway
implic
pulmonari
inflamm
bronchoconstrict
includ
pathway
flap
product
leukotrien
lt
two
class
ltcysteinyl
leukotrien
cyslt
ltb
inflammatori
lipid
mediat
gener
arachidon
acid
aa
pathway
activ
immun
cell
aa
membran
phospholipid
catalyz
phospholipas
convers
lta
mast
cell
macrophag
eosinophil
basophil
convert
molecul
cyslt
ltc
precursor
cysteinyl
leukotrien
ltd
lte
although
potenc
vari
differ
set
three
cyslt
stimul
airway
smooth
muscl
contract
increas
vascular
permeabl
neutrophil
convert
lta
ltb
act
potent
neutrophil
monocyt
chemoattract
increas
cyslt
product
associ
acut
asthma
like
reflect
activ
inflammatori
cell
present
airway
viral
asthma
exacerb
two
class
cyslt
r
cyslt
r
classic
g
proteincoupl
receptor
cyslt
human
cyslt
r
predomin
cyslt
receptor
airway
express
airway
smooth
muscl
cell
macrophag
mast
cell
ltd
predomin
ligand
receptor
increas
intracellular
calcium
smooth
muscl
contract
monteleukast
cyslt
r
antagonist
shown
improv
lung
function
patient
present
emerg
depart
exacerb
provid
evid
immunopatholog
role
cyslt
acut
asthma
enzym
catalyz
product
cyslt
also
target
drug
inhibitor
zileuton
number
flap
inhibitor
current
develop
cholinerg
system
involv
bronchial
constrict
mucu
product
via
activ
muscarin
receptor
acetylcholin
ach
releas
peribronchi
parasympathet
nerv
fiber
ach
also
produc
nonneuron
airway
epitheli
cell
anticholinerg
longact
muscarin
receptor
antagonist
lama
tiotropium
bromid
reduc
cholinerg
activ
impact
airway
smooth
muscl
tone
mucu
hypersecret
block
neuron
acetylcholin
tiotropium
also
report
reduc
nonneuron
ach
augment
goblet
cell
metaplasia
airliquid
interfac
ali
differenti
airway
epitheli
cell
cultur
human
clinic
trial
bronchodilatori
activ
saba
could
augment
use
lama
improv
treatment
outcom
children
adult
acut
moder
sever
exacerb
sever
persist
poorli
control
asthma
addit
tiotropium
highdos
combin
therapi
improv
lung
function
hour
inhal
tiotropium
bromid
demonstr
efficaci
treatment
chronic
obstruct
pulmonari
diseas
copd
exacerb
phase
iii
human
clinic
trial
asthma
provid
sustain
bronchodil
whilst
reduc
frequenc
exacerb
inhal
tiotropium
bromid
licens
use
addon
therapi
adult
mainten
combin
therapi
least
one
sever
exacerb
previou
year
number
anticholinerg
drug
includ
glycopyrronium
seebri
aclidinium
bromid
forest
laboratori
almiral
umeclidinium
bromid
glaxosmithklin
therav
also
approv
treatment
copd
variou
stage
develop
prevent
asthma
exacerb
xanthin
deriv
nonselect
phosphodiesteras
inhibitor
demonstr
therapeut
efficaci
patient
respond
well
corticosteroid
phosphodiesteras
inhibit
reduc
inflamm
bronchoconstrict
increas
effect
combin
therapi
theophyllin
may
therefor
use
treatment
virusinduc
asthma
one
mechan
action
includ
upregul
histon
deacetylas
express
defici
thought
underli
steroid
resist
patient
use
drug
limit
interact
numer
drug
narrow
therapeut
rang
variabl
pharmacokinet
extens
side
effect
recognit
asthma
heterogen
diseas
implic
individu
diseas
manag
base
detail
phenotyp
character
deriv
immunopathogen
mechanist
insight
good
evid
persist
atop
sensit
associ
activ
immun
key
driver
asthma
children
asthmat
adult
repres
far
heterogen
popul
even
immun
signatur
report
approxim
adult
asthmat
cytokin
produc
cell
critic
mani
respons
drive
allerg
airway
inflamm
diseas
asthma
requir
ige
synthesi
requir
eosinophil
recruit
matur
surviv
requir
mast
cell
activ
induc
airway
hyperreact
ahr
mucu
hypersecret
metaplasia
mucusproduc
cell
innat
immun
cell
particularli
recent
discov
innat
lymphoid
cell
recogn
anoth
import
sourc
cytokin
associ
pathogenesi
allerg
airway
diseas
recruit
lung
allergen
challeng
respond
produc
high
level
two
semin
studi
assess
whether
allergen
exposur
increas
risk
acut
asthma
conjunct
viral
infect
sensit
asthmat
green
et
al
investig
patient
age
admit
acut
exacerb
assess
presenc
respiratori
infect
well
total
allergenspecif
ige
combin
sensit
exposur
high
level
common
household
environment
allergen
viral
infect
strongli
associ
risk
hospit
admitt
acut
asthma
similar
find
children
age
year
also
report
murray
cowork
indic
synerg
sensit
allergen
exposur
viral
infect
induc
asthma
exacerb
studi
human
experiment
rv
infect
model
allerg
asthmaticand
normalvolunt
demonstr
asthmat
sever
lower
respiratori
tract
symptom
reduct
lung
function
increas
bronchial
hyperreact
exacerb
sever
strongli
correl
bal
cell
cytokin
product
viral
load
use
direct
sampl
techniqu
could
demonstr
increas
airway
mucosa
asthmat
experiment
infect
rv
express
cytokin
upper
lower
respiratori
tract
associ
sever
asthma
symptom
variou
promis
antibodybas
therapi
treatment
virusinduc
asthma
exacerb
current
develop
licens
use
next
gener
asthma
treatment
includ
monoclon
antibodi
target
specif
inflammatori
molecul
defin
asthma
phenotyp
allerg
asthma
common
form
diseas
ige
play
central
role
allerg
inflamm
activ
mast
cell
basophil
crosslink
ige
promot
degranul
releas
proinflammatori
mediat
lead
increas
inflamm
omalizumab
xolair
first
approv
usa
monoclon
antibodi
bind
neutral
ige
thu
prevent
activ
omalizumab
reduc
serumfre
ige
level
bind
constant
region
prevent
ige
interact
receptor
addit
earli
studi
group
subject
allerg
dust
mite
show
treatment
omalizumab
reduc
serumfre
ige
also
decreas
express
circul
basophil
subject
omalizumab
shown
effect
reduc
asthma
exacerb
improv
symptom
control
reduc
need
ic
betaagonist
phase
ii
phase
iii
trial
sever
atop
asthmat
recent
expert
panel
guidelin
recommend
consid
omalizumab
altern
addit
oral
corticosteroid
step
v
vi
patient
sever
allerg
asthma
two
studi
examin
prophylact
treatment
report
signific
reduct
exacerb
caus
viral
infect
omalizumabtr
group
one
studi
identifi
associ
increas
product
fewer
exacerb
omalizumab
treatment
group
implic
inhibit
crosslink
ige
involv
respons
mechan
link
igereceptor
bind
regul
ifn
product
viral
infect
asthma
investig
plasmacytoid
dendrit
cell
pdc
crucial
innat
immun
cell
produc
larg
amount
type
ifn
respons
viral
infect
observ
activ
could
inhibit
abil
pdc
secret
respons
stimul
gill
colleagu
extend
observ
demonstr
defici
influenzainduc
ifn
induct
pdc
asthmat
subject
compar
healthi
subject
confirm
crosslink
led
profound
inhibit
viru
induct
studi
show
crosslink
pbmc
children
asthma
defici
rvinduc
ifn
product
suggest
omalizumab
could
also
use
enhanc
pdc
mediat
antivir
respons
treatment
virusinduc
asthma
exacerb
well
establish
cytokin
effector
molecul
drive
allerg
inflamm
asthma
biolog
target
cytokin
focu
treatment
develop
cytokin
produc
activ
mast
cell
basophil
eosinophil
dendrit
cell
cell
cytokin
signal
play
central
role
promot
allerg
diseas
increas
ige
product
cell
differenti
mast
cell
dendrit
cell
develop
eosinophil
recruit
ahr
anim
studi
shown
knockout
mice
unabl
develop
eosinophilia
make
attract
target
atop
asthma
treatment
despit
promis
result
preclin
studi
clinic
trial
human
mab
pascolizumab
show
littl
efficaci
treat
asthma
human
clinic
trial
appear
effect
suppress
eosinophil
infiltr
administ
allergen
challeng
inhibit
minim
effect
reduc
eosinophil
infiltr
evid
block
reduc
diseas
virusinduc
asthma
number
human
mab
also
enter
clinic
trial
particular
astrazeneca
tralokinumab
enter
phase
iii
clinic
trial
studi
includ
adult
moder
sever
uncontrol
asthma
subcutan
inject
tralokinumab
improv
lung
function
mean
sd
increas
baselin
fev
l
l
l
mg
dose
respect
compar
placebo
also
greater
reduct
use
agonist
patient
treat
tralokinumab
similarli
lebrikizumab
anoth
human
mab
genentech
also
show
lung
function
improv
use
patient
high
level
molecul
periostin
addit
lebrikizumab
treatment
also
reduc
asthma
exacerb
rate
periostinhigh
patient
signal
given
key
role
play
pathogenesi
asthma
mab
target
develop
efficaci
dupilumab
evalu
asthmat
patient
persist
moder
sever
eosinophil
diseas
studi
patient
treat
dupilumab
mg
patient
receiv
placebo
treatment
administ
week
patient
instruct
discontinu
laba
ic
week
week
respect
end
point
measur
includ
asthma
exacerb
lung
function
marker
result
trial
promis
dupilumabtr
patient
experienc
reduct
exacerb
addit
dupilumab
also
improv
lung
function
asthma
control
reduc
express
biomark
associ
inflamm
addit
promot
allerg
inflamm
cytokin
interfer
antivir
immun
one
studi
found
inhibit
interferon
product
increas
viru
replic
increas
rv
replic
also
observ
mice
allerg
airway
inflamm
rv
one
common
trigger
asthma
exacerb
need
determin
block
could
use
prevent
experiment
rvinduc
exacerb
asthma
regul
eosinophil
matur
surviv
increas
sputum
eosinophil
correl
asthma
exacerb
sever
mab
mepolizumab
gsk
reslizumab
teva
pharmaceut
receptor
alpha
benralizumab
astrazeneca
enter
phase
iii
clinic
trial
treat
asthmat
high
eosinophil
level
random
doubleblind
studi
patient
eosinophil
asthma
recurr
exacerb
administ
either
mg
intraven
dose
mg
subcutan
dose
mepolizumab
placebo
everi
week
week
treatment
mepolizumab
decreas
blood
eosinophil
count
halv
exacerb
rate
increas
lung
function
improv
asthma
control
mepolizumab
complet
phase
iii
clinic
trial
licens
usa
trade
name
nucala
sinc
novemb
addon
mainten
therapi
sever
eosinophil
asthma
similarli
block
receptor
benralizumab
mg
mg
reduc
exacerb
rate
adult
uncontrol
eosinophil
asthma
eosinophil
promin
inflammatori
cell
virusinduc
asthma
exacerb
one
studi
eosinophil
airway
infiltr
persist
week
follow
infect
asthmat
individu
correl
increas
airway
hyperrespons
recent
human
experiment
rv
infect
studi
report
substanti
increas
bal
eosinophil
number
asthmat
subject
target
treat
virusinduc
eosinophil
asthma
exacerb
current
investig
eg
mepolizumab
treatment
rhinovirusinduc
asthma
exacerb
clinic
trialsgov
airway
epitheli
cell
possess
capac
directli
influenc
immun
express
cytokin
tslp
shown
express
cytokin
link
viral
replic
bronchial
epithelium
respons
inflamm
asthma
exacerb
translationaltreat
develop
perspect
airway
epithelium
attract
site
drug
deliveri
inhal
therapi
numer
advantag
system
deliveri
approach
demonstr
pulmonari
inflamm
broadli
suppress
inhal
drug
mab
target
immuneactiv
cytokin
express
bronchial
epithelium
major
advanc
current
cytokinetarget
approach
reli
system
deliveri
larg
dose
expens
antibodi
famili
member
identifi
initi
regul
immun
studi
demonstr
increas
gene
express
togeth
receptor
tissu
inflamm
eosinophil
mast
cell
airway
epithelium
also
report
sourc
within
lung
block
mous
model
prior
antigen
sensit
andor
challeng
caus
strike
reduct
cell
respons
cytokin
product
potent
activ
immun
stimul
cytokin
product
via
activ
cell
report
asthmat
bec
express
increas
level
rv
infect
show
block
receptor
mab
mous
model
rvinduc
asthma
exacerb
prevent
virusinduc
increas
allerg
inflamm
cytokin
product
signal
subunit
also
known
type
associ
accessori
protein
infect
influenza
induc
innat
popul
respond
produc
recent
perform
experiment
rv
infect
atop
asthmat
healthi
human
subject
observ
express
protein
bronchial
mucos
line
fluid
associ
increas
cytokin
product
asthma
exacerb
symptom
sever
vitro
block
activ
mab
suppress
product
cytokin
cell
stimul
medium
rvinfect
asthmat
bec
tslp
first
epitheli
cytokin
observ
express
asthma
mice
transgen
overexpress
tslp
airway
induc
inflamm
lead
skew
naiv
cell
becom
cell
tlsp
activ
dendrit
cell
via
heterodimer
receptor
compos
tslpr
lead
prime
recruit
cell
via
product
chemokin
observ
rv
infect
increas
tslp
express
lung
mice
allerg
pulmonari
inflamm
antitslp
mab
demonstr
therapeut
efficaci
human
studi
experiment
allergendriven
asthma
block
studi
demonstr
role
tlsp
amplif
pulmonari
inflamm
airway
diseas
viral
infect
asthma
far
lack
earlylif
viral
wheez
ill
risk
factor
asthma
develop
jackson
et
al
examin
relationship
earlylif
virusinduc
wheez
asthma
develop
atrisk
parent
histori
respiratori
allergyasthma
cohort
children
coast
studi
show
rv
infect
confer
greatest
probabl
odd
ratio
asthma
develop
age
respiratori
viral
infect
also
caus
asthma
exacerb
precis
mechan
viral
infect
make
asthma
wors
still
poorli
understood
one
reason
difficulti
inher
repeatedli
sampl
lower
airway
accur
measur
presenc
infecti
viru
exacerb
nonetheless
inhibit
viral
replic
reduc
virusinduc
inflamm
sensibl
approach
treatment
stimul
antivir
immun
potenti
therapi
unlik
immuneblock
approach
describ
earlier
aim
precis
stimul
innat
antivir
immun
therebi
limit
replic
inhibit
product
asthmogen
immun
mediat
idea
tolllik
receptor
detect
infect
induc
express
innat
antivir
interferon
play
key
role
reduc
viral
load
via
induct
antivir
molecul
directli
initi
typei
immun
respons
antagon
immun
associ
pulmonari
allerg
inflamm
major
caveat
immunestimulatori
approach
potenti
promot
inflamm
caus
wors
diseas
clearli
antiviralimmuneregulatori
versu
inflammatori
profil
drug
categori
need
meticul
assess
preclin
move
human
asthma
trial
tolllik
receptor
tlr
recogn
rang
bacteri
viral
compon
critic
detect
pathogen
activ
innat
immun
cell
although
import
clearanc
pathogen
activ
tlr
could
act
doubleedg
sword
especi
set
chronic
lung
diseas
exampl
activ
viral
doublestrand
rna
bacteri
compon
lp
link
increas
airway
inflamm
mous
model
convers
activ
may
protect
asthma
play
import
role
antivir
immun
predominantli
express
pdc
bcell
also
express
airway
epitheli
cell
reduc
function
associ
asthma
preclin
studi
treatment
agonist
mous
model
allerg
asthma
prevent
develop
airway
resist
leukocyt
infiltr
suppress
product
type
cytokin
shown
allerg
mice
display
impair
ifn
releas
upon
infect
increas
viru
replic
eosinophil
inflamm
airway
hyper
reactiv
treatment
exogen
ifn
adopt
transfer
pdc
block
exagger
inflammatori
respons
express
lung
suppress
allerg
inflamm
eosinophilia
absenc
allergi
examin
endobronchi
biopsi
subject
moderatetosever
asthma
eosinophil
neutrophil
airway
inflamm
despit
inhal
steroid
show
reduc
ifn
lambda
express
furthermor
express
invers
correl
percentag
sputum
eosinophil
impli
airway
eosinophilia
act
neg
regul
express
antivir
respons
provid
molecular
mechan
underpin
effect
eosinophiltarget
treatment
prevent
asthma
exacerb
chronic
allerg
asthma
model
pretreat
agonist
ovalbumin
antigen
challeng
also
prevent
airway
remodel
goblet
cell
hyperplasia
increas
airway
smooth
muscl
mass
similar
acut
allerg
asthma
model
agonist
pretreat
also
reduc
type
type
cytokin
chronic
model
apart
role
innat
immun
also
mediat
human
airway
smooth
muscl
relax
dosedepend
manner
given
promot
antivir
defens
protect
virusinduc
airway
dysfunct
agonist
viabl
therapeut
option
virusinduc
asthma
exacerb
support
mous
studi
show
defici
lead
sever
rvinduc
airway
diseas
hous
dustmit
allerg
mice
effect
could
revers
type
type
iii
ifn
treatment
gsk
develop
select
agonist
test
phase
trial
involv
patient
allerg
rhiniti
intranas
deliveri
ng
stimul
type
ifn
isg
express
without
caus
symptomat
inflamm
recogn
bacteri
viral
cpgdna
predominantli
express
airway
epithelium
macrophag
neutrophil
pdc
bcell
murin
model
asthma
found
agonist
treatment
allergen
challeng
markedli
reduc
lung
eosinophilia
cytokin
product
airway
hyperreact
studi
show
cpgdna
also
suppress
subepitheli
fibrosi
goblet
cell
hyperplasia
key
featur
airway
remodel
remain
studi
agonist
could
use
treat
viralinduc
asthma
innat
antivir
type
interferon
play
import
role
sever
biolog
process
antiprolif
antivir
immunomodulatori
activ
type
ifn
import
compon
innat
immun
respons
viru
induc
upon
stimul
pattern
recognit
receptor
prr
bacteria
viral
compon
type
ifn
receptor
consist
two
subunit
receptor
ifnar
subunit
subunit
upon
bind
ligand
type
ifn
signal
proteintyrosin
kinas
tyk
phosphoryl
form
heterodim
transloc
nucleu
bind
promot
isg
mani
isg
involv
inhibit
viral
replic
import
isg
viral
pathogenesi
summar
review
evid
suggest
type
express
rvinfect
bec
impair
asthma
identifi
potenti
import
protect
role
type
ifn
signal
asthma
exacerb
studi
identifi
mechan
impair
ifn
express
shown
suppressor
cytokin
signal
induc
either
rv
infect
inflammatori
cytokin
suppress
promot
activ
bec
addit
express
increas
bronchial
biopsi
specimen
adult
mild
moder
atop
asthma
prompt
conclus
increas
express
neg
regul
contribut
ifn
defici
asthma
type
iii
ifn
anoth
group
innat
antivir
ifn
signal
distinct
receptor
complex
compos
analysi
ex
vivo
rvinfect
asthmat
bec
bronchoalveolar
lavag
bal
cell
contoli
et
al
demonstr
impair
rvinduc
type
iii
ifn
correl
increas
symptom
viral
load
declin
lung
function
rv
infect
vivo
patient
subsequ
studi
employ
mous
model
demonstr
exogen
express
could
reduc
sever
allerg
airway
diseas
via
modul
dcmediat
differenti
cell
type
interferon
also
restrict
type
immunopatholog
act
mice
defici
type
ifn
signal
demonstr
increas
type
immunopatholog
follow
infect
influenza
viru
recent
two
separ
studi
simultan
report
neg
regul
activ
turn
reduc
inflamm
preval
defect
ifn
express
univers
normal
ifn
express
asthma
observ
studi
even
report
increas
children
wheez
viral
infect
compar
children
whose
viral
diseas
confin
upper
respiratori
tract
express
posit
correl
diseas
sever
author
conclud
evid
drive
diseas
whilst
possibl
author
unabl
measur
viral
load
lower
airway
determin
increas
stimul
higher
viral
replic
wheez
children
interact
ifnexpress
viral
replic
effect
diseas
complex
influenc
anoth
import
factor
appear
diseas
sever
discrep
identifi
ifn
defici
asthma
attribut
asthma
sever
mild
wellcontrol
asthma
less
like
exhibit
phenotyp
although
still
much
learn
role
ifn
viral
asthma
exacerb
molecul
obviou
therapeut
option
potenti
restor
defici
ifn
express
improv
control
viral
infect
suppress
allerg
airway
diseas
clinic
trial
investig
effect
type
interferon
therapi
asthmat
studi
recruit
particip
histori
coldinduc
asthma
exacerb
treat
either
nebul
placebo
within
hour
onset
cold
symptom
differ
observ
placebotr
group
term
asthma
control
questionnair
howev
ifn
treatment
enhanc
morn
peak
respiratori
flow
recoveri
reduc
need
addit
treatment
boost
innat
immun
assess
blood
sputum
biomark
note
intent
treat
analysi
popul
reveal
major
cold
fail
develop
signific
exacerb
analysi
subgroup
persist
asthma
moder
greater
sever
show
deterior
symptom
peak
flow
cold
treatment
significantli
improv
peak
flow
prevent
virusinduc
asthma
symptom
result
suggest
interferon
therapi
might
use
treat
subset
asthmat
persist
poor
control
despit
treatment
greater
risk
acut
exacerb
larg
phase
iii
random
control
trial
underway
determin
almost
acut
asthma
episod
children
preced
virusinduc
cold
adult
data
less
comprehens
virus
still
predomin
caus
asthma
attack
group
respiratori
virus
obviou
target
advanc
treatment
asthma
exacerb
directli
inhibit
viral
infect
would
obviat
need
block
downstream
inflammatori
cytokin
boost
antivir
immun
approach
come
set
challeng
least
number
virus
caus
exacerb
includ
rv
influenza
rsv
human
metapneumoviru
parainfluenza
viru
adenoviru
coronaviru
whilst
virus
detect
equal
term
frequenc
associ
acut
asthma
viral
asthma
particularli
children
caus
rv
infect
block
infect
group
virus
would
substanti
impact
virusinduc
asthma
exacerb
current
antivir
drug
avail
rv
intercellular
adhes
express
epitheli
cell
endotheli
cell
leukocyt
neutrophil
express
crucial
recruit
activ
cell
express
natur
ligand
includ
macrophag
adhes
ligand
express
macrophag
granulocyt
leukocyt
functionassoci
antigen
express
tcell
extracellular
matrix
protein
also
natur
receptor
speci
ab
rv
classifi
major
group
virus
therefor
target
could
altern
treat
viralinduc
asthma
note
infect
rva
subtyp
rvc
speci
virus
would
inhibit
previou
work
show
administr
antihuman
antibodi
target
domain
human
abl
block
entri
reduc
cellular
inflamm
proinflammatori
cytokin
product
viral
replic
transgen
mous
express
chimer
humanmous
protein
confer
permiss
administr
antihuman
success
prevent
exacerb
allerg
airway
inflamm
airway
hyperrespons
mice
remain
determin
approach
translat
human
clinic
trial
initi
interest
treatment
rv
infect
stem
need
reduc
burden
common
cold
number
drug
includ
pirodavir
design
bind
viral
capsid
inhibit
attach
uncoat
product
infect
result
clinic
trial
gener
disappoint
develop
discontinu
anoth
antirhinovir
compound
pleconaril
capsid
binder
prevent
virion
uncoat
made
phase
ii
clinic
trial
subject
administ
pleconaril
within
hour
viral
cold
result
studi
promis
signific
reduct
symptom
score
howev
drug
approv
due
complic
aris
interact
oral
contracept
anoth
drawback
emerg
drugresist
mutant
compani
merck
sharp
dohm
corp
fund
phase
ii
studi
conduct
assess
effect
pleconaril
nasal
spray
cold
asthma
exacerb
reduct
rvposit
asthma
exacerb
report
renew
interest
develop
capsidbind
antirhinovir
specif
treatment
patient
chronic
respiratori
diseas
asthma
biota
pharmaceut
current
test
small
molecul
enteroviru
capsid
inhibitor
vapendavir
phase
ii
clinic
trial
involv
approxim
asthmat
trial
due
complet
march
year
frequenc
asthma
exacerb
one
endpoint
assess
rupintrivir
agouron
pharmaceut
inc
proteas
inhibitor
design
inhibit
proteolyt
cleavag
viral
polyprotein
therebi
prevent
rv
replic
frequent
deliveri
drug
nasal
spray
cold
treatment
reduc
symptom
nasal
viral
secret
interest
rupintrivir
treatment
enteroviru
coxsackieviru
caus
agent
hand
foot
mouth
diseas
common
afflict
amongst
infant
young
children
efficaci
rupintrivir
treatment
viral
asthma
report
resveratrol
natur
phenol
stilbenoid
produc
number
plant
respons
damag
infect
compound
report
inhibit
rv
replic
nasal
epithelia
potenti
glucocorticosteroid
activ
far
studi
molecul
limit
vitro
anim
model
vaccin
provid
lifelong
immunolog
protect
holi
grail
prevent
treatment
virusinduc
asthma
exacerb
given
predomin
rv
diseas
effect
vaccin
viru
would
enorm
impact
success
vaccin
mani
import
viral
diseasesso
rv
one
princip
barrier
vaccin
develop
viral
divers
rv
group
within
enteroviru
genu
encompass
speci
rva
b
c
cover
genet
distinct
subtyp
base
capsid
protein
sequenc
rv
capsid
consist
structur
protein
largest
primari
target
neutral
antibodi
rv
capsid
protein
exhibit
substanti
antigen
divers
result
antibodi
respons
rv
similarli
divers
fact
speci
b
divid
immunolog
distinct
serotyp
serolog
respons
rvc
virus
character
similar
level
antigen
divers
like
exist
virus
exist
rv
serotyp
explain
human
remain
suscept
infect
throughout
life
despit
antigen
divers
natur
occur
antibodi
cross
reactiv
detect
human
serum
antibodi
respons
vari
amongst
individu
presum
rv
infect
histori
subject
differ
protect
infect
assess
immun
peptid
deriv
rv
capsid
protein
also
gener
crossreact
antibodi
howev
crossreact
limit
rv
subtyp
neutral
thu
becom
increasingli
clear
complet
protect
vaccin
rv
need
incorpor
neutral
antibodi
epitop
multipl
rv
subtyp
across
three
viral
speci
major
challeng
vaccin
design
recent
altern
gener
mucos
neutral
antibodi
consid
rv
vaccin
design
base
gener
protect
cell
main
attract
explor
approach
rv
precursor
nonstructur
protein
sequenc
highli
conserv
therefor
like
gener
broadli
protect
immun
reduc
complex
vaccin
formul
requir
broad
spectrum
protect
investig
use
rv
infect
model
mice
immun
rva
precursor
observ
induct
crossspeci
rva
rvb
cell
respons
enhanc
product
speci
b
virusspecif
neutral
antibodi
follow
infect
immun
mice
rvb
viru
also
observ
challeng
tcellbas
rv
vaccin
develop
includ
time
requir
mobil
effect
cell
respons
rv
potenti
respons
enhanc
lung
inflamm
exacerb
asthma
symptom
respiratori
viru
infect
usual
confin
upper
respiratori
tract
caus
mild
selflimit
condit
commonli
refer
cold
suscept
individu
chronic
lower
respiratori
diseas
asthma
infect
exacerb
symptom
requir
increas
medic
profession
medic
intervent
clear
vast
major
asthma
exacerb
trigger
viral
infect
common
human
rv
particularli
case
children
acut
wheez
ill
remain
amongst
common
caus
hospit
age
six
combin
atopi
recur
episod
wheez
viru
infect
particular
rv
strongli
associ
develop
asthma
later
life
bronchoconstrict
airway
inflamm
underpin
diseas
acut
viral
asthma
current
prevent
therapeut
strategi
consist
drug
relax
airway
smooth
muscl
revers
airway
constrict
broad
spectrum
antiinflammatori
corticosteroid
reduc
impact
patholog
immun
mediat
mani
asthmat
combin
approach
control
symptom
reduc
impact
viral
infect
howev
subpopul
asthmat
tend
sever
diseas
difficult
control
standard
treatment
group
suscept
viral
exacerb
constitut
biggest
burden
term
morbid
mortal
health
care
cost
associ
asthma
address
need
new
treatment
option
summar
figur
much
research
focus
develop
monoclon
antibodi
mab
inhibit
key
immun
mediat
asthma
combin
research
defin
asthma
immun
phenotyp
proven
critic
therapeut
efficaci
new
biolog
antiig
omalizumab
xolair
advanc
recommend
use
addon
therapi
persist
moder
sever
atop
asthma
xolair
shown
reduc
incid
asthma
exacerb
howev
specif
effect
viral
asthma
exacerb
known
mab
cytokin
mepolizumab
complet
phase
iii
clinic
trial
begun
licens
use
airway
epithelium
site
respiratori
viru
infect
asthmat
airway
epitheli
cell
respond
aberrantli
infect
produc
inflammatori
mediat
potenti
instrument
initi
asthma
attack
strategi
develop
address
includ
mab
target
promot
cytokin
tslp
adjuv
innat
epitheli
antivir
immun
tlr
agonist
recogn
rv
infect
far
frequent
caus
viral
asthma
particularli
children
directli
target
rv
antivir
gener
protect
immun
antirv
vaccin
approach
consid
structuralantigen
divers
amongst
approxim
rv
subtyp
present
substanti
challeng
antivir
drugand
vaccinedevelop
much
achiev
current
asthma
therapi
particular
use
moder
dose
ic
icslaba
combin
enough
improv
asthma
control
reduc
risk
exacerb
problem
acut
exacerb
asthma
particular
role
viru
infect
trigger
event
remain
import
unmet
need
next
five
year
emerg
monoclon
antibodi
therapi
target
airway
inflamm
direct
potenti
continu
becom
avail
clinic
use
expect
benefit
substanti
reduct
exacerb
frequenc
patient
control
icslaba
alon
greater
understand
role
emerg
cytokin
particular
tslp
acut
asthma
exist
monoclon
antibodi
also
like
see
deploy
set
prevent
asthma
exacerb
possibl
treat
regard
specif
treatment
target
acut
viral
infect
asthma
effect
nebul
either
antivir
agent
immun
modifi
known
applic
direct
antivir
agent
vaccin
strategi
appear
unlik
within
timefram
perhap
except
vapendavir
current
phase
ii
clinic
test
unclear
whether
strategi
impact
group
first
year
life
experi
frequent
episod
virusinduc
airway
diseas
may
play
crucial
role
develop
adult
asthma
clinic
benefit
demonstr
young
children
challeng
due
difficulti
recruit
age
group
regular
inject
omalizumab
may
hold
promis
modifi
develop
asthma
exist
strong
associ
atopi
virusinduc
wheez
develop
persist
asthma
later
year
standard
treatment
adrenerg
receptor
agonist
inhal
corticosteroid
evolv
littl
recent
decad
exacerb
continu
caus
disproportion
larg
burden
diseas
asthma
recognis
heterogen
diseas
encompass
rang
phenotyp
driven
distinct
immunopatholog
mechan
drive
develop
novel
biolog
personalis
treatment
directli
target
virus
prevent
treat
exacerb
technic
challeng
due
viral
structuralantigen
divers
interferon
therapi
broad
spectrum
potenti
overcom
problem
structuralantigen
divers
airway
epithelium
site
viral
infect
initi
inflammatori
cascad
exacerb
target
promot
cytokin
airway
epithelium
offer
real
hope
develop
new
treatment
emerg
therapi
cytokin
targetingmab
antiig
type
iiii
ifn
show
real
promis
improv
treatment
exacerb
establish
asthma
howev
therapeut
efficaci
viral
wheez
preasthmat
young
children
complet
unknown
prevent
reduc
level
infect
use
antivir
approach
either
block
infect
promot
antivir
immun
attract
option
technic
challeng
infect
proce
caus
releas
target
cytokin
tslp
activ
either
directli
via
dendrit
cell
dc
innat
lymphoid
cell
cell
primari
sourc
cytokin
cytokin
stimul
patholog
respons
ige
product
monoclon
antibodi
mab
target
cytokin
mepolizumab
ige
omalizumab
antiig
licenc
use
asthma
